Lenacapavir, trialed in Uganda, offers 100% protection but will it reach those who need it most? Kampala, Uganda | RONALD ...

A landmark breakthrough in HIV prevention received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effective that global health leaders had started ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has announced that it has signed an access agreement with Pharmaceutical Company Gilead Sciences to procure lenacapavir, a ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

There are over 100,000 HIV+ Texans. Trump's 'big beautiful' bill would slash funding for federal HIV prevention, medications, ...

A modest pullback for US stocks Friday eased the market from all-time highs and left major stock indexes on Wall Street in ...

Global AIDS Update shows that 30% of surveyed Indians aged 15-49 reported facing stigma. Domestic violence, little autonomy over healthcare among key concerns of women with HIV.

Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

President Trump signed the budget bill, but the White House now demands Congress rescind more than $9 billion — including $400 million that funds America’s international ...

Every 10 minutes, an adolescent girl or young woman is infected with HIV in South Africa. But a long-acting injection could ...